| 000 | 01291 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250514210122.0 | ||
| 264 | 0 | _c20050217 | |
| 008 | 200502s 0 0 eng d | ||
| 022 | _a0269-2813 | ||
| 024 | 7 |
_a10.1111/j.1365-2036.2004.02192.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAspinall, R J | |
| 245 | 0 | 0 |
_aThe management of side-effects during therapy for hepatitis C. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _cNov 2004 |
||
| 300 |
_a917-29 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xadverse effects |
| 650 | 0 | 4 |
_aDepressive Disorder _xchemically induced |
| 650 | 0 | 4 | _aDrug Carriers |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHematologic Diseases _xchemically induced |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadverse effects |
| 650 | 0 | 4 | _aPolyethylene Glycols |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aRibavirin _xadverse effects |
| 700 | 1 | _aPockros, P J | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 20 _gno. 9 _gp. 917-29 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2036.2004.02192.x _zAvailable from publisher's website |
| 999 |
_c15209854 _d15209854 |
||